Article
Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study.
Journal of cancer research and clinical oncology - 17 Jan 2024
Lei Jiaying, Wang Wenxia, Lin Danna, Zhu Chengguang, Jia Wenguang, Weng Wenjun, Liu Xiaoshan, Ma Yuhan, Wang Zhixuan, Yang Lihua, He Xiangling, He Yunyan, Li Yang
Abstract excerpt
BACKGROUND: Langerhans cell histiocytosis (LCH) is a myeloid neoplasia with potentially fatal consequences, and about 2/3 of cases involve the BRAFV600E kinase-activated mutation. Vemurafenib, a BRAF inhibitor, has demonstrated significant clinical improvements in LCH. However, the high relapse rate of LCH following cessation of vemurafenib therapy remains a major challenge, and alternative treatment strategies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.